Your Messages Inbox
Your Article Summary
See Latest ArticlesBlood cell manufacture: current methods and future challenges
Trends in Biotechnology , 07/06/09
Timmins NE et al. - Current yields are orders of magnitude too low for production of meaningful quantities, and the physical scale of the problem is a challenge in itself. The authors discuss these challenges in relation to current methods and how it might be possible to realize limited 'blood pharming' of neutrophils in the near future.
Today in Biotechnology...keeping you current
Receive free subspecialty "5-minute updates" via email
Safety First in Biotech Development
BioPharm, 12/03/09
Teva Announces The Submission Of A Biologics License Application (BLA) For XM02 For The Treatment Of Chemotherapy-Induced Neutropenia
Teva Pharmaceutical Industries, 12/02/09
Complete Genomics and GATC Biotech Collaborate on Human Genome Sequencing Projects
b3c newswire, 12/02/09
Article Search
Sponsor